In the ever-evolving field of wound care, chronic wounds present some of the most persistent and challenging cases for healthcare providers. These wounds, which include diabetic foot ulcers, venous leg…
POMPANO BEACH, Fla., Nov. 08, 2023 — BioStem Technologies Inc. (OTC:BSEM), a leading regenerative medicine company focused on the development, manufacture and commercialization of placental-derived biologics for advanced wound care, today…
POMPANO BEACH, Fla., May 29, 2024 (GLOBE NEWSWIRE) — BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental-derived biologics, will…
– Company Achieves Record-Breaking First Quarter Results for 2024, Marking the Launch of BioStem 2.0 –– Company Reports First Quarter EBITDA of $4.9 Million –– Project Continued Growth from Sales…
Better Processing leads to Better Results Diabetic foot ulcers (DFUs) pose a daunting challenge for both patients and healthcareproviders, significantly impacting quality of life and increasing the risk of complications….
Current Good Tissue Practices Current Good Tissue Practices (CGTP) are governing methods and practices outlined by the US Food and Drug Administration (FDA). US-based tissue manufacturers are required to follow…
